




• Independent	 validation	 in	 small	 samples,	 such	 as	 with	 3	 events	 among	 10	patients,	is	merely	window-dressing	
• Simulations	confirm	that	at	least	100	events	and	100	non-events	are	required	for	reliable	assessment	of	predictive	performance	
• In	very	large	samples,	overall	independent	validation	is	of	minor	relevance,	since	we	 should	 be	 interested	 in	 assessment	 of	 heterogeneity	 in	model	 performance	across	settings	rather	than	the	average		
What	this	adds	to	what	was	known?	
• Prediction	 models	 often	 perform	 poorly	 when	 assessed	 in	 external	 validation	studies	
• Independent	 validation	 is	 often	 performed	 by	 randomly	 splitting	 a	 data	 set	 to	assess	validity	in	independent	data	
• Such	 split	 sample	 validation	 is	 performed	 while	 it	 is	 known	 to	 be	 inefficient,	reflecting	 insufficient	 perception	 of	 the	 goals	 of	 validation	 in	 small	 and	 large	samples		
What	is	the	implication	and	what	should	change	now?	
• Independent	validation	should	be	abolished	for	validation	of	prediction	models	












# Simulation, May 2018 
library(rms) 
 
i <- 100000 # sufficient precision 
Results  <- matrix(nrow=i, ncol=3) 
set.seed(1) 
 
for (j in 1:i) { # start simulation 
n0 <- 7 
n1 <- 3 
X0 <- rnorm(n0 , 0, 1) # controls, no event 
X1.7 <- rnorm(n1 , 0.7416145, 1) # true c = 0.7 
X1.8 <- rnorm(n1 , 1.190232, 1)  # true c = 0.8 
X1.9 <- rnorm(n1 , 1.812388, 1)  # true c = 0.9 
 
## ROC area ### 
Results[j, 1] <- rcorr.cens(x=c(X0,X1.7), S=c(rep(0,n0), rep(1,n1)), outx=F)[1] 
Results[j, 2] <- rcorr.cens(x=c(X0,X1.8), S=c(rep(0,n0), rep(1,n1)), outx=F)[1] 
Results[j, 3] <- rcorr.cens(x=c(X0,X1.9), S=c(rep(0,n0), rep(1,n1)), outx=F)[1] 
} # end simulation 
 
# Count complete separation 
mean(Results[,1]==1) # 6.2% 
mean(Results[,2]==1) # 14.8% 
mean(Results[,3]==1) # 35.4% 
############################# 
 
## Repeat with 100 events 
# Simulation 
i = 100000 
Results100  <- matrix(nrow=i, ncol=3) 
set.seed(1) 
 
for (j in 1:i) { # start simulation 
  n0 <- 233 
  n1 <- 100 # 0.3 event rate 
  X0 <- rnorm(n0 , 0, 1) 
  X1.7 <- rnorm(n1 , 0.7416145, 1) 
  X1.8 <- rnorm(n1 , 1.190232, 1) 
  X1.9 <- rnorm(n1 , 1.812388, 1) 
   
  ## ROC area ### 
  Results100[j, 1] <- rcorr.cens(x=c(X0,X1.7), S=c(rep(0,n0), rep(1,n1)), outx=F)[1] 
  Results100[j, 2] <- rcorr.cens(x=c(X0,X1.8), S=c(rep(0,n0), rep(1,n1)), outx=F)[1] 
  Results100[j, 3] <- rcorr.cens(x=c(X0,X1.9), S=c(rep(0,n0), rep(1,n1)), outx=F)[1   
} # end simulation 




apply(Results, 2, function(x)mean(x<.5)) #15, 5, 0.6% 
apply(Results, 2, function(x)quantile(x, probs = c(0.025, 0.975))) # lower limits 0.29, 0.43, 
0.62 
apply(Results100, 2, function(x)quantile(x, probs = c(0.025, 0.975))) 
 
## Same for 500 events ## 
 
##################################### 
# Plot results for 3 and 100 events # 
library(lattice)  
Results.combi <- c(Results[,1], Results[,2], Results[,3], 
                       Results100[,1], Results100[,2], Results100[,3]) 
Results.combi <- as.data.frame(cbind(c(rep(3, 3* i), rep(100, 3* i)),  
                                     c(rep(0.7, i), rep(0.8, i), rep(0.9, i), 
                                       rep(0.7, i), rep(0.8, i), rep(0.9, i)), Results.combi)) 
 
dimnames(Results.combi)[[2]] <- c("Events", "AUC", "Estimates") 
 
Results.combi[,1] <-factor(Results.combi[,1],levels=c(3,100),labels=c("3 events","100 
events")) 
Results.combi[,2] <-factor(Results.combi[,2],levels=c(0.7, 0.8, .9), 
labels=c("C=0.7","C=0.8","C=0.9"))  
                                                       
histogram(~ Estimates | AUC + Events, data = Results.combi, xlim=c(0.25,1.06), nint = 22) 
 
densityplot(~ Estimates | AUC + Events, data = Results.combi, plot.points = F, 
            xlim=c(0.25,1.06) ) 
# End simple simulation study #	  
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